Want to see IN:SENORES full AI Analyst Report?
Top Page
Senores Pharmaceuticals Ltd.
(SENORES)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹1,511.00
▲(110.77% Upside)
Action:Reiterated
Date:09/13/26
The score is held back primarily by weak cash-flow execution (persistent, large negative free cash flow and low cash conversion despite strong FY2026 reported profitability). Technicals are moderately constructive with the stock above key longer-term moving averages and neutral momentum. Valuation is a notable headwind given the high P/E and lack of dividend yield support.
Positive Factors
FY2026 revenue and margin expansion
The sharp increase in revenue and strong FY2026 margins indicate materially greater operating scale and earnings capacity. If these economics persist, the company can reinvest in growth, strengthen its market position, and generate higher profits over the next several quarters.
Negative Factors
Persistently negative free cash flow
Sustained deeply negative free cash flow shows that reported profitability is not translating into cash available for debt reduction, dividends, or reinvestment. Continued cash consumption could require funding support and limits financial flexibility even while earnings remain strong.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 revenue and margin expansion
The sharp increase in revenue and strong FY2026 margins indicate materially greater operating scale and earnings capacity. If these economics persist, the company can reinvest in growth, strengthen its market position, and generate higher profits over the next several quarters.
Read all positive factors
Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)
Market Cap
₹67.58B
Dividend YieldN/A
Average Volume (3M)14.65K
Price to Earnings (P/E)51.6
Beta (1Y)0.94
Revenue Growth51.74%
EPS Growth77.53%
CountryIN
Employees368
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)10.35
Shares Outstanding46,053,590
10 Day Avg. Volume15,602
30 Day Avg. Volume14,651
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)34.4
Revenue Forecast (FY)₹9.07B
Senores Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches ma...
Senores Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 2.52B | 6.33B | 3.83B |
| Gross Profit | 1.29B | 3.81B | 14.11M |
| EBITDA | 849.50M | 2.15B | 1.08B |
| Net Income | 502.10M | 1.15B | 6.85M |
Balance Sheet | |||
| Total Assets | 12.88B | 16.04B | 145.66M |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.32B | 3.85B |
| Total Debt | 2.41B | 3.42B | 3.15B |
| Total Liabilities | 4.54B | 6.39B | 50.70M |
| Stockholders Equity | 8.14B | 9.34B | 7.86B |
Cash Flow | |||
| Free Cash Flow | -2.27B | -2.03B | -2.03B |
| Operating Cash Flow | -280.86M | 620.50M | -459.20M |
| Investing Cash Flow | -3.34B | -1.21B | -4.29B |
| Financing Cash Flow | 4.39B | -13.30M | 5.73B |
Senores Pharmaceuticals Ltd. Technical Analysis
Positive
716.90
Price Trends
1432.09
Positive
1265.62
Positive
1031.20
Positive
Market Momentum
13.43
Positive
51.84
Neutral
48.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SENORES, the sentiment is Positive. The current price of 716.9 is below the 20-day moving average (MA) of 1486.91, below the 50-day MA of 1432.09, and below the 200-day MA of 1031.20, indicating a neutral trend. The MACD of 13.43 indicates Positive momentum. The RSI at 51.84 is Neutral, neither overbought nor oversold. The STOCH value of 48.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SENORES.
Senores Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹543.69B | 33.62 | ― | 2.05% | 6.29% | 11.18% | |
80 Outperform | ₹148.77B | 28.87 | ― | 0.27% | 19.59% | 47.58% | |
56 Neutral | ₹67.58B | 51.56 | ― | ― | 51.74% | 77.53% | |
56 Neutral | ₹43.48B | 41.23 | ― | 0.09% | 10.25% | 33.78% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹11.37B | 45.50 | ― | 1.27% | 11.96% | -28.48% |
* General Sector Average
IN:SENORES
Senores Pharmaceuticals Ltd.
1,467.45
784.15
114.76%
IN:ABBOTINDIA
Abbott India Limited
25,586.10
-4,633.55
-15.33%
IN:KOPRAN
Kopran Limited
235.55
63.91
37.24%
IN:MARKSANS
Marksans Pharma Limited
328.30
154.53
88.93%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,039.05
-1,166.53
-22.41%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
464.30
173.25
59.53%
Senores Pharmaceuticals Ltd. Corporate Events
Senores Pharmaceuticals Releases Q1 FY27 Earnings Call Transcript
Aug 3, 2026
Senores Pharmaceuticals Ltd. notified stock exchanges that it has released the official transcript of its Q1 FY27 earnings conference call, held on July 27, 2026. The document has been submitted under regulatory disclosure norms and is also availa...
Senores Pharmaceuticals Files Q1FY27 Investor Presentation With Indian Stock Exchanges
Jul 27, 2026
Senores Pharmaceuticals Limited has released its investor presentation for the first quarter of fiscal year 2027, following an earlier intimation of its earnings conference call. The presentation, now available on the company’s website and s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.